Capivasertib, a potent, selective inhibitor of all AKT isoforms (AKT1/2/3) [5, 6], demonstrated efficacy in combination with fulvestrant for the treatment of hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative breast cancer and with paclitaxel for the treatment of triple-negative breast cancer (TNBC) in clinical phase 2 trials with an intermittent capivasertib dose regimen of 400 mg twice daily (BID) given 4 days on, 3 days off [4/3] [7, 8]. This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.